A prospective observational study on host immunity for development of novel immunotherapeutic strategy in patients with severe respiratory tract infections and sepsis
- Conditions
- Community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), coronavirus disease 2019 (COVID-19), and sepsis
- Registration Number
- JPRN-UMIN000046739
- Lead Sponsor
- agoya University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 650
Not provided
1) Patients who do not receive initial empirical antibiotic treatment 2) Patients with obstructive pneumonia 3) Pneumonia or sepsis occurred in other hospitals and patients who were transferred from other hospitals with a trend toward improvement 4) Patients whose pneumonia or sepsis recurred within 3 days after the last day of antibiotic treatment of a preceding pneumonia or sepsis episode 5) Patients who receive the treatment in outpatient clinics 6) Patients who were enrolled in this study previously 7) Patients over 90 years old 8) HIV positive patients 9) Pregnant women 10) Patients with neutropenia (neutrophil counts <1,000/mm3) 11) Patients with active hematologic malignancies 12) Patients after blood stem cell transplants, including bone marrow transplants 13) Patients treated for co-morbidities with high-dose glucocorticoid
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Clinical outcomes Death, progression to severe state, secondary adverse events, and treatment failure 2) Immunological outcome Association between host immune characteristics and clinical outcomes
- Secondary Outcome Measures
Name Time Method